

August 13,2020

National Stock Exchange of India Ltd  
Listing Department  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No: C/1  
G - Block, Bandra - Kurla Complex  
Bandra (East)  
Mumbai - 400 051.

BSE Limited  
Corporate Relationship Department  
1st floor, New Trading Ring  
Rotunda Building, P J Towers  
Dalal Street, Fort  
Mumbai - 400 001

Dear Sir/Madam

**SUB: SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018**  
**Fund raising by issuance of debt securities by Large Entities**


With reference to above SEBI Circular dated November 26, 2018 in respect of fund raising by issuance of debt securities by Large Corporates (LC), we hereby submit that Orchid Pharma Limited ("the Company") does not fall under Large Corporates (LC) category as per the framework provided in the aforesaid circular.

Further, we are enclosing herewith Annexure A as required under the aforesaid circular.

Kindly take the above on your records.

Thanking you,

Yours faithfully,

  
Sunil Kumar Gupta  
Chief Financial Officer



**Annexure A**
**Format of the Initial Disclosure to be made by an entity identified as a Large Corporate**

Sr. No.	Particulars	Details
1	Name of the Company	Orchid Pharma Limited
2	CIN	L24222TN1992PLC022994
3	Outstanding borrowing of company as on 31st March/ 31st December, as applicable (in Rs. cr)	Rs.427 Crores
4	Highest Credit Rating during the previous FY along with name of the Credit Rating Agency	Credit rating not applicable as the Company was under Corporate Insolvency Resolution Process (CIRP) till 30/03/2020 during the previous year under the IBC, 2016.
5	Name of Stock Exchange# in which the fine shall be paid. in case of shortfall in the required borrowing under the framework	Not Applicable

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.

Nikita K  
 Company Secretary  
 nikitak@orchidpharma.com

  
 Sunil Kumar Gupta  
 Chief Financial Officer  
 sunilgupta@orchidpharma.com

Date: 13.08.2020

# - In terms of para 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.